Immunocore is still driven mainly by KIMMTRAK, but late-stage trials in other cancers and moves into infectious and autoimmune diseases could turn it into a multi-product biotech over time. The big question is whether the next wave of study results and reimbursement decisions arrive fast enough to offset rising research costs and growing competition.Read more
Immunocore’s growth leans heavily on a single cancer drug, and tougher rules on what health systems will pay—especially in Europe—could squeeze future sales and profits. At the same time, faster-moving rival therapies and uncertain trial outcomes could decide whether its wider pipeline can reduce that dependence in time.Read more
Key Takeaways Potential for much higher market penetration and revenue growth than consensus due to superior product tolerability and strong real-world performance. Broad, late-stage pipeline with diverse indications and platform advantages could drive significant earnings growth and strategic partnership or acquisition interest.Read more
No trending discussion available.
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
